20-Jan-2021 09:14 AM
Healthcare company Alliance Pharma said it expected underlying pre-tax profit to marginally top market expectations following 'strong' performance from its consumer healthcare brands.
See-through revenue for 2020 was down 5% on the prior year
22-Sep-2020 09:32 AM
Alliance Pharma reported a slump in first-half profit owing to the impact of the pandemic, though the healthcare group said that it was now seeing signs of recovery.
For the six months ended 30 June 2020, pre-tax profit fell 96% to £0.6m on-year
21-Jul-2020 09:49 AM
Healthcare group Alliance Pharma reported that first-half revenue was hurt by the COVID-19 pandemic, but continued to expect a further recovery in the second half of the year.
For the six months ended 30 June 2020, revenue fell 7% to £65.3 on-ye
18-May-2020 01:52 PM
Health care group Alliance Pharma said its revenue had fallen as expected due to the Covid-19 crisis.
The company, however, had also been 'encouraged by the robustness of our product portfolio',' chief excutive Peter Butterfield said in AG
22-Jan-2020 09:43 AM
Healthcare group Alliance Pharma said it expected to report 15% growth in annual revenue and underlying profit in line with its expectations.
Revenue for the year through December was seen rising to £135.6m, the company said. Excluding acquisitions
17-Jul-2019 09:36 AM
Alliance Pharma said it expected revenues to rise by more than fifth in the first half of the year amid growth from its consumer healthcare products.
For the first half of 2019 revenues were expected to rise 29% to £70.3m from a year earlier and
23-May-2019 09:17 AM
Alliance Pharma it continued to trade 'well,' amid continued growth from its International Star brands and a 'solid' performance from its local brands. The company also confirmed that it had not benefit from any price increases in proc
01-May-2019 08:50 AM
Numis today upgrades its investment rating on Alliance Pharma PLC (LON:APH) to buy (from add).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
26-Mar-2019 02:12 PM
Healthcare group Alliance Pharma booked a 19% drop in annual profit owing to asset write-downs, though its underlying performance improved.
Pre-tax profit for the year through December fell to £22.8m, even as revenue rose 16% to £118.2m.
Adj
19-Sep-2018 09:04 AM
Alliance Pharma reported Wednesday a marginal increase in first-half profit amid higher costs related to acquisition of Vamousse and continued investment in the company's International Star Brands.
For the six months ended 30 June, profit before tax
25-Jul-2018 02:33 PM
Specialty pharmaceuticals group Alliance Pharma said it expected to post a 10% rise in first-half revenue, though the rate of profit growth would be lower due to spending on sales and marketing.
Revenue for the six months through June was seen growing to
13-Jul-2018 10:10 AM
Numis today reaffirms its add investment rating on Alliance Pharma PLC (LON:APH) and raised its price target to 115p (from 99p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
07-Jun-2018 12:30 PM
Numis today downgrades its investment rating on Alliance Pharma PLC (LON:APH) to add (from buy) and raised its price target to 99p (from 88p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
09-May-2018 07:31 AM
Venture Life announced its manufacturing contract with Alliance Pharma has been extended until 2025.
The company also secured additional business in excess of that currently undertaken for Alliance.
Alliance is an international pharmaceutical company sp
17-Apr-2018 12:20 PM
Numis today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and raised its price target to 88p (from 80p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
11-Jan-2018 07:57 AM
Hardman Research has issued a report on Alliance Pharma.
It says: 'Alliance Pharma is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cash generative, specialty pharma b
28-Dec-2017 07:33 AM
Alliance Pharma's its wholly-owned subsidiary, Alliance Pharmaceuticals Ltd, has completed the acquisition of the worldwide rights to Vamousse from TyraTech.
Alliance also announced the appointment of Amanda Sicvol as country manager for its newly
12-Dec-2017 08:20 AM
finnCap today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and raised its price target to 70p (from 58p).
Story provided by StockMarketWire.com...
04-Dec-2017 12:30 PM
Numis today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and set its price target at 71p.
Story provided by StockMarketWire.com...
04-Dec-2017 07:11 AM
Alliance Pharma's wholly owned subsidiary, Alliance Pharmaceuticals Limited, has agreed to acquire the worldwide rights to Vamousse from TyraTech Inc for an initial consideration of US$13.0m and deferred contingent consideration of up to US$4.5m.
01-Dec-2017 09:50 AM
Numis today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and set its price target at 66p.
Story provided by StockMarketWire.com...
01-Dec-2017 07:56 AM
Alliance Pharma's wholly-owned subsidiary, Alliance Pharmaceuticals, has acquired all of the rights to Ametop from global medical technology business Smith & Nephew for $7.5m. Ametop is a topical anaesthetic gel product used for numbing the skin pr
13-Sep-2017 07:52 AM
Alliance Pharma's revenues rose by 8% to £50.3m in the six months to the end of June.
EBITDA increased by 3% to £13.6m and net debt was reduced by £12.7m to £63.4m.
The group has declared an interim dividend of 0.443p per
31-Jul-2017 09:00 AM
finnCap today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and cut its price target to 58p (from 65p).
Story provided by StockMarketWire.com...
25-May-2017 09:41 AM
Alliance Pharma's cash flow remains strong and it is on target to reduce adjusted net debt/EBITDA ratio to around 2x by the end of the year, shareholders at the annual general meeting will be told.
Chairman Andrew Smith will say: "The year is p